Press Releases :: Sutro Biopharma, Inc. (STRO)

Dec 8, 2020 9:10 pm EST

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

Dec 7, 2020 4:00 pm EST

Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

Dec 7, 2020 10:00 am EST

Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting

Dec 3, 2020 4:30 pm EST

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Dec 1, 2020 7:00 am EST

Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors

Nov 24, 2020 7:00 am EST

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

Nov 18, 2020 7:00 am EST

Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations

Nov 11, 2020 7:00 am EST

Sutro Biopharma to Participate in Four Upcoming Investor Conferences

Nov 5, 2020 7:00 am EST

Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments

Sep 21, 2020 7:00 am EDT

Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC